Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia.

doi:10.1186/s13045-020-00992-1

Back to search

Article

Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia.

Journal of hematology & oncology - 19 Nov 2020

Gebru Melat T, Wang Hong-Gang

Abstract excerpt

Acute myeloid leukemia (AML) is a heterogeneous disease caused by several gene mutations and cytogenetic abnormalities affecting differentiation and proliferation of myeloid lineage cells. FLT3 is a receptor tyrosine kinase commonly overexpressed or mutated, and its mutations are associated with...

Topics

Animals
Antineoplastic Agents
Drug Resistance, Neoplasm
Humans
Leukemia, Myeloid, Acute
Molecular Targeted Therapy
Mutation
Protein Kinase Inhibitors
Signal Transduction
fms-Like Tyrosine Kinase 3

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.